HC Wainwright & Co. Reiterates Buy on Halozyme Therapeutics, Maintains $60 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Mitchell Kapoor has reiterated a 'Buy' rating on Halozyme Therapeutics (NASDAQ:HALO) and maintained a $60 price target.
September 08, 2023 | 11:06 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Halozyme Therapeutics has been reiterated with a 'Buy' rating by HC Wainwright & Co. The price target remains at $60.
The reiteration of a 'Buy' rating and maintenance of a $60 price target by HC Wainwright & Co. indicates a positive outlook for Halozyme Therapeutics. This could potentially lead to an increase in investor confidence and a positive impact on the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100